MAPT and Alzheimer disease: To further explore the utility of plasma Aβ, Aβ42, and tau levels for AD diagnosis across age and population, we developed new statistical models that incorporated age along with the levels of these biochemical analytes to establish cut-off values for identifying AD in the combined data from the BSHRI and NTUH cohorts.